Document is current
Any future updates will be listed below
-
Authors
Kumarathurai, Preman http://orcid.org/0000-0002-2463-5110
Sajadieh, Ahmad
Anholm, Christian
Kristiansen, Ole P.
Haugaard, Steen B. http://orcid.org/0000-0002-6827-7036
Nielsen, Olav W. http://orcid.org/0000-0003-3532-9431
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01595789 at ClinicalTrials.govDocuments that mention this clinical trial
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
https://doi.org/10.1136/bmjopen-2014-005942
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
https://doi.org/10.1186/s13098-019-0438-6
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
https://doi.org/10.1186/s12933-020-01205-2
-
Funding
Funding for this research was provided by:
Novo Nordisk Investigator Initiated Studies
Hjerteforeningen
A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- License Information
-
More Information
Article History
Received: 11 September 2020
Accepted: 24 December 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: This study was approved by the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark and the Danish Medicines Agency. The study was carried out in accordance with the ICH-GCP (International Conference on Harmonization-Good Clinical Practice) standards. Written informed consent was obtained from each subject.
: All authors gave consent for publication.
: SBH has received funding of educational and research tasks from Novo Nordisk, Abbott, Eli Lilly, Pfizer, Boehringer-Ingelheim, Bristol-Meyers Squibb and Merck, Sharp & Dome. OWN has received funding of educational and research tasks from Resmed and participated in advisory boards for Novartis Pharma. PK, CA, OPK and AS have nothing to disclose.
